Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat.
Long-term effects of bezafibrate on in vivo production of VLDL-triglyceride were studied in the rat. Bezafibrate given at a daily dose of 30 mg/kg body weight for 14 days produced a decrease not only in triglyceride by 51% but in cholesterol by 28% and phospholipid by 18%. Despite a marked reduction in plasma triglyceride concentrations, there was no significant change in the rate of VLDL-triglyceride secretion from the liver into the circulation between bezafibrate-treated and control animals (1113 +/- 58 and 1234 +/- 63 micrograms/min, respectively). In addition, bezafibrate produced no change in lipid composition in VLDL. These results suggest that bezafibrate enhances triglyceride removal from the circulation, which leads to reduction in plasma triglyceride.
Department of Medicine, Hyogo Medical Center for Adults, Akashi, Japan.
T
T
Kazumi
G
G
Yoshino
M
M
Iwai
K
K
Matsuba
M
M
Matsushita
I
I
Iwatani
T
T
Kasama
M
M
Yoshida
S
S
Baba
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003902:Detergents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D008079:Lipoproteins, VLDL / Q000096:biosynthesis*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010743:Phospholipids / Q000097:blood; D011092:Polyethylene Glycols / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D014280:Triglycerides / Q000096:biosynthesis* / Q000097:blood
D001786:Blood Glucose; D008076:Cholesterol, HDL; D003902:Detergents; D007328:Insulin; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D011092:Polyethylene Glycols; D002784:Cholesterol; C016811:tyloxapol; D001629:Bezafibrate